InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain
InhaleRX Ltd has received approval for a Phase 2 clinical trial to test its novel therapy IRX-211 for treatment of Breakthrough Cancer Pain
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Announcements
Filter Results
CRG | Annual Report & Financial Statements: 30 June 2024 (Price Sensitive) | PRICE SENSITIVE | 16/09/24 | |
CRG Annual Report & Financial Statements: 30 June 2024 (Price Sensitive) | |||
16/09/24 | PRICE SENSITIVE | ||